GIGAGEN

In News

Grifols ponies up $80M for polyclonal antibody biotech GigaGen - Fierce Biotech

Fierce Biotech - Mar 10, 2021

GigaGen Doses First Patient in Phase 1 Trial of GIGA-2339, a Potential Functional Cure for Chronic Hepatitis B - Contagion Live

Contagion Live - Nov 25, 2024

Innovating Biothreat Therapies: An Interview with Head of GigaGen - The Clinical Trial Vanguard

The Clinical Trial Vanguard - Oct 17, 2024

Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug - news.wisc.edu

news.wisc.edu - Sep 09, 2020

GigaGen Doses First Patient in Phase 1 Trial of Recombinant - GlobeNewswire

GlobeNewswire - Nov 19, 2024

Recombinant polyclonal antibodies for viral diseases - Drug Discovery News

Drug Discovery News - Mar 25, 2024

GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment - Clinical Trials Arena

Clinical Trials Arena - Nov 20, 2024

Peninsula biotech reels in potential $135 million contract to be first line of treatment against bioterrorism - The Business Journals

The Business Journals - Oct 03, 2024

Generation of recombinant hyperimmune globulins from diverse B-cell repertoires - Nature

Nature - Apr 15, 2021

Unleashing the potential of lab-grown recombinant polyclonal antibodies - drugtargetreview.com

drugtargetreview.com - Jul 17, 2024

GigaGen Announces New Office Space in South San Francisco - PR Newswire

PR Newswire - Jan 23, 2018

GigaGen Works to Develop Passive, Convalescent COVID-19 Therapy - BioSpace

BioSpace - Mar 30, 2020

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment